2-O-beta-D-吡喃葡萄糖基-alpha-D-吡喃葡萄糖 | 20880-64-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2-O-beta-D-吡喃葡萄糖基-alpha-D-吡喃葡萄糖
• 英文名称: sophorose
• 英文别名: α-sophorose；alpha-Sophorose；(2S,3R,4S,5S,6R)-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-2,4,5-triol
• CAS: 20880-64-2
• 化学式: C₁₂H₂₂O₁₁
• mdl: MFCD00150664
• 分子量: 342.3
• InChiKey: HIWPGCMGAMJNRG-NCFXGAEVSA-N

物化性质

• 熔点：
  200°C
• 溶解度：
  可溶于氯仿（轻微、加热、超声处理）、甲醇（轻微）

计算性质

• 辛醇/水分配系数(LogP)：
  -4.2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  190
• 氢给体数：
  8
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  2-O-beta-D-吡喃葡萄糖基-alpha-D-吡喃葡萄糖 在 sodium tetrahydroborate 作用下， 生成 sophoritol
  参考文献：
  名称：

  Co-ordinated synthesis of gentiobiitol and sorbitol, evidence of sorbitol glycosylation in transgenic sugarcane

  摘要：

  Sugarcane (a Saccharum spp. interspecific hybrid) was previously engineered to synthesize sorbitol (designated as sorbitolcane). Motivated by the atypical development of the leaves in some sorbitolcane, the polar metabolite profiles in the leaves of those plants were compared against a group of control sugarcane plants. Eighty-six polar metabolites were detected in leaf extracts by GC-MS. Principal component analysis of the metabolites indicated that three compounds were strongly associated with sorbitolcane. Two were identified as sorbitol and gentiobiose and the third was unknown. Gentiobiose and the unknown compound were positively correlated with sorbitol accumulation. The unknown compound was only abundant in sorbitolcane. This compound was structurally characterized and found to be a sorbitol-glucose conjugate. C-13 NMR analysis indicated that the glucopyranose and glucitol moieties were 1,6-linked. Ligand exchange chromatography confirmed that the compound was a beta-anomer, thus identifying the compound as 6-O-beta-D-glucopyranosyl-D-glucitol, or gentiobiitol. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.phytochem.2010.01.014
• 作为产物：
  描述：

  benzyl 2-O-β-D-glucopyranosyl-α-D-glucopyranoside 在 钯 氢气 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以83%的产率得到2-O-beta-D-吡喃葡萄糖基-alpha-D-吡喃葡萄糖
  参考文献：
  名称：

  Synthesis of benzyl α- and β-sophorosides, and of benzyl α-laminarabioside

  摘要：

  DOI：

  10.1016/s0008-6215(00)84592-9

文献信息

• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160051691A1

  公开（公告）日：2016-02-25

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

  本发明提供了包含至少一个式(I)的亚单位的iRNA试剂： 其中： A和B分别独立于每次出现O、N(RN)或S； X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R； R是LG、-连接子-LG，或具有下面所示结构： LG独立于每次出现的是一种碳水化合物，例如，单糖、双糖、三糖、四糖、寡糖、多糖； RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基； Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
• POLYMER-CARBOHYDRATE CONJUGATES FOR DRUG DELIVERY TECHNOLOGY
  申请人：Wu Nian

  公开号：US20150157721A1

  公开（公告）日：2015-06-11

  The invention comprises compounds, methods of making, and methods of using. The compounds may have a linear or cylic backbone and three or four appended functional groups: one or two lipohilic compounds including sterols or “fat soluble” vitamins, one or two hydrophilic polymer, and one or two carbohydrate. A group of polymer-carbohydrate conjugates having a central backbone and three appended functional groups are disclosed wherein one lipophilic compound is void of both steroid acids. The conjugate may have fatty acids as the primary lipophilic carrier, one hydrophilic polymer, and one carbohydrate. Specific functional groups may be selected for specific applications in formulating pharmaceuticals, cosmetics, nutriceuticals, and the like. Typical coupling reaction of the conjugates may involve one or more or combinations or in series of alkylation including N-alkylation or O-alkylation, etherification, esterification and amidation chemical processes. A variety of linkers between the backbone and functional groups may also be selected to modify the carriers or center backbones for the coupling reactions and optimize performance of the conjugates.

  该发明包括化合物、制备方法和使用方法。这些化合物可能具有线性或环状的骨架，以及三个或四个附加的功能基团：一个或两个疏水化合物，包括固醇或“脂溶性”维生素，一个或两个亲水性聚合物，以及一个或两个碳水化合物。公开了一组具有中心骨架和三个附加功能基团的聚合物-碳水化合物共轭物，其中一个疏水性化合物不含类固醇酸。该共轭物可能以脂肪酸作为主要疏水载体，一个亲水性聚合物和一个碳水化合物。特定的功能基团可以根据在制备药物、化妆品、营养保健品等方面的具体应用而选择。共轭物的典型偶联反应可能涉及一种或多种或组合或串联的烷基化，包括N-烷基化或O-烷基化，醚化，酯化和酰胺化化学过程。还可以选择各种连接剂连接骨架和功能基团之间，以修改载体或中心骨架以进行偶联反应并优化共轭物的性能。
• [EN] TREATMENT OF INFECTIONS<br/>[FR] TRAITEMENT D'INFECTIONS
  申请人：ASCENDIS PHARMA AS

  公开号：WO2020064844A1

  公开（公告）日：2020-04-02

  The present invention relates among other aspects to a conjugate or a pharmaceutically acceptable salt thereof or a pharmaceutical composition comprising said conjugate or its pharmaceutically acceptable salt for use in a method of preventing or treating an infection, wherein said conjugate is water-insoluble and comprises a polymeric moiety -Z to which a plurality of moieties -L2-X0D-L1-D are covalently conjugated, wherein each -D is independently an antibiotic moiety; each -L1- is independently a linker moiety to which -D is covalently and reversibly conjugated; each -X0D- is independently absent or a linkage and each -L2- is independently either a chemical bond or a spacer moiety.

  本发明涉及一种共轭物或其药用可接受的盐，或包含所述共轭物或其药用可接受的盐的药物组合物，用于预防或治疗感染的方法，其中所述共轭物不溶于水，包括一个聚合物基团-Z，其中多个基团-L2-X0D-L1-D以共价结合方式共轭，其中每个-D独立地是抗生素基团；每个-L1-独立地是连接基团，与-D以共价和可逆方式结合；每个-X0D-独立地不存在或是一个连接，每个-L2-独立地是化学键或间隔基团。
• Charged sophorolipids and sophorolipid containing compounds
  申请人：Zerkowski Jonathan

  公开号：US20070027106A1

  公开（公告）日：2007-02-01

  A sophorolid produced by a method involving reacting a compound of formula I with a compound of formula II wherein R 1 and R 2 are H, C 1 -C 18 alkyl, C 3 -C 18 alkenyl, C 3 -C 10 cycloalkyl, phenyl, or C 1 through C 18 acyl or alkoxycarbonyl, R 1 and R 2 are not both acyl, R 3 is H, CH 3 , CH 2 -phenyl, CH 2 —C 6 H 4 —OH, CH 2 CO 2 H, CH 2 CH 2 CO 2 H, CH(CH 3 ) 2 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , CH 2 OH, CH(CH 3 )OH, CH 2 CH 2 CH 2 CH 2 NH 2 , CH 2 CH 2 CONH 2 , CH 2 CONH 2 , CH 2 —C 3 N 2 H 3 (histidine), CH 2 CH 2 CH 2 NHC(NH)NH 2 , CH 2 CH 2 SCH 3 , R 2 and R 3 may be joined in a ring, R 4 is H, C 1 -C 18 alkyl, C 3 -C 18 alkenyl, C 3 -C 10 cycloalkyl, or phenyl, n is 0-6, R 5 and R 6 are H, C 1 -C 18 alkyl, C 3 -C 18 alkenyl, C 3 -C 10 cycloalkyl, or phenyl, and X is C 1 -C 18 alkyl or C 1 -C 18 alkenyl; optionally followed by acidolytic (treating with an acid) or hydrogenolytic deprotection (treating with a hydrogenolysis catalyst) which removes one of the groups R 1 or R 2 and replaces it with hydrogen. Also a sophorolipid containing composition containing a carrier and at least one sophorolipid described above.

  通过一种涉及将式I化合物与式II化合物反应的方法生产的一种索福罗脂，其中R1和R2为H、C1-C18烷基、C3-C18烯基、C3-C10环烷基、苯基或C1-C18酰基或烷氧羰基，R1和R2不同时为酰基，R3为H、CH3、CH2-苯基、CH2—C6H4—OH、CH2CO2H、CH2CH2CO2H、CH(CH3)2、CH2CH(CH3)2、CH(CH3)CH2CH3、CH2OH、CH(CH3)OH、CH2CH2CH2CH2NH2、CH2CH2CONH2、CH2CONH2、CH2—C3N2H3（组氨酸）、CH2CH2CH2NHC(NH)NH2、CH2CH2SCH3，R2和R3可连接成环，R4为H、C1-C18烷基、C3-C18烯基、C3-C10环烷基或苯基，n为0-6，R5和R6为H、C1-C18烷基、C3-C18烯基、C3-C10环烷基或苯基，X为C1-C18烷基或C1-C18烯基；可选择性地接着酸解（用酸处理）或氢解保护（用氢解催化剂处理），去除R1或R2中的一个基团，并用氢替换之。还有一种含有载体和上述至少一种索福罗脂的索福罗脂含有组合物。
• FLUORESCENT ANTICANCER PLATINUM DRUGS
  申请人：INVICTUS ONCOLOGY PVT. LTD.

  公开号：US20180312534A1

  公开（公告）日：2018-11-01

  The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to fluorescent platinum based compounds. The disclosure further relates to synthesis of said fluorescent platinum based compounds, nanoparticles and compositions comprising said fluorescent platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by the fluorescence changes between aforesaid platinum based compounds and corresponding free ligands, nanoparticles and compositions.

  本公开涉及纳米技术和癌症治疗领域。具体而言，本公开涉及荧光铂基化合物。该公开进一步涉及合成所述荧光铂基化合物、纳米颗粒和包含所述荧光铂基化合物/纳米颗粒的组合物。该公开还涉及通过上述铂基化合物与相应的游离配体、纳米颗粒和组合物之间的荧光变化来管理癌症的方法。